Galderma buys ZO Skin Health as Galderma stock trades at EUR 186.50

Published on 10/16/2026 at 09:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Galderma reports pediatric Nemluvio data sustained through Week 52. Galderma stock represents CHF 40.2 billion in market value on October 16, 2026.

Acquisition and growth evidence

Galderma agreed to acquire ZO Skin Health for USD 1.5 billion on October 14, 2026.
First-half 2026 net sales rose 24.60 percent and full-year growth guidance is 19.00-21.00 percent.
Galderma stock trades at EUR 186.50 at 9:40 a.m. CEST at Lang & Schwarz on October 16, 2026.
Third-quarter results are scheduled for October 22, 2026.
Galderma's market capitalization is CHF 40.2 billion as of October 16, 2026.

Galderma, CH1335392721, Illustration mit AI erstellt.

Galderma (ISIN CH1335392721) was trading at EUR 186.50 at Lang & Schwarz on October 16, 2026 at 9:40 a.m. CEST, while its latest company announcements put portfolio expansion and Nemluvio development at the center of the investment case. On October 14, Galderma announced an agreement to acquire ZO Skin Health for USD 1.5 billion.

Three events frame the stock

On September 21, 2026, Galderma entered the Swiss Market Index after reporting first-half 2026 sales growth of 24.60 percent and raising full-year growth guidance to 19.00-21.00 percent from 17.00-20.00 percent. On October 14, 2026, the company agreed to buy 100 percent of ZO Skin Health for USD 1.5 billion in cash, with closing expected in the fourth quarter of 2026 or early 2027. On October 15, 2026, Galderma reported pediatric nemolizumab data showing itch-response rates of 56.00-72.00 percent at Week 16, with results sustained through Week 52.

What does the acquisition add?

ZO expands Galderma's physician-dispensed skincare portfolio alongside Alastin and adds a brand with approximately USD 330.0 million in sales during the 12 months ended June 2026. The transaction is expected to be neutral for core earnings per share in the first full year after closing, but Galderma expects a slight reduction in its core EBITDA margin in 2027 before a comparable margin from 2028.

The operating backdrop gives the deal a measurable growth benchmark. In the first half of 2026, Galderma generated USD 3.1 billion in net sales, while core EBITDA reached USD 802.0 million, up 42.80 percent year over year, according to the company's reported results summarized by Yahoo Finance.

Next reporting date is October 22

Galderma's next scheduled reporting event is third-quarter 2026 results on October 22, 2026, according to MarketScreener. Before that update, the market will be weighing whether the ZO transaction can add growth without weakening the margin profile that supported the higher 2026 outlook.

Galderma stock price in euros

Galderma's market capitalization was CHF 40.2 billion as of October 16, 2026, while the primary SIX quotation had a 52-week range of CHF 134.70 to CHF 188.25. The euro quotation was trading at EUR 186.50 at Lang & Schwarz on October 16, 2026 at 9:40 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Galderma stock.